Procoralan (ivabradine)
- Region
- 🇪🇺 EU
- Active substance
- ivabradine
- Company
- Les Laboratoires Servier
- Status
- Authorised
- Therapeutic area
- Angina Pectoris; Heart Failure
- EU approval
- Tue 25 Oct 2005
- Application
- EMEA/H/C/000597
- ATC
- C01EB17
- Official record
- www.ema.europa.eu
Indication
Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated : in adults unable to tolerate or with a contraindication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ivabradine Anpharm Authorised · "Anpharm" Przedsiębiorstwo Farmaceutyczne S.A.
- 🇪🇺 Corlentor Authorised · Les Laboratoires Servier
- 🇪🇺 Ivabradine Zentiva Authorised · Zentiva k.s.
- 🇪🇺 Ivabradine Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Ivabradine JensonR Withdrawn · JensonR+ Limited
Follow Procoralan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.